{"id":44778,"date":"2023-02-01T07:30:22","date_gmt":"2023-02-01T07:30:22","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=44778"},"modified":"2023-04-10T19:10:00","modified_gmt":"2023-04-10T19:10:00","slug":"integrase-inhibitors-associated-with-higher-increases-in-cd4cd8-ratio-than-pi-or-nnrti-based-art","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/44778","title":{"rendered":"Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART"},"content":{"rendered":"
\n
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

A retrospective analysis of 3,907 participants starting or switching ART in an observational Canadian cohort study between 2006 to 2017 reported higher CD4:CD8 ratio responses compared to PI- or NNRTI-based ART.<\/span><\/strong><\/p>\n<\/div>\n

\n

The study included used dual NRTIs in all combinations with the third drug being an NNRTI, PI, or INSTI in 25%, 51% and 24% of participants, respectively. The INSTIs in the analysis were raltegravir (38%), elvitegravir (19%) and dolutegravir (43%).<\/span><\/p>\n<\/div>\n

\n

The analysis adjusted for all standard demographic and HIV-related variables, including calendar year and previous treatment history in people switching ART.<\/span><\/p>\n<\/div>\n

\n

After 13,640 person-years of follow-up, 1790\/3907 participants had a CD4:CD8 ratio >1.0 after a median of 4.4 years (IQR: 2.1 to 7.4). Overall, the median (IQR) follow-up was 5.8 years (3.1 to 8.4), 4.5 years (2.0 to 7.4) and 2.9 years (1.7 to 5.3) for NNRTI, PI and INSTI groups, respectively.<\/span><\/p>\n<\/div>\n

\n

The adjusted hazard ratio (HR) for the achieving a CD4:CD8 ratio >1.0 compared to INSTI-based ART was 0.56 (95%CI: 0.48 to 0.65) for NNRTI- and 0.41 (95% CI: 0.35 to 0.47) for PI-based ART.<\/span><\/p>\n<\/div>\n

\n

The results were similar using the CD4:CD8 ratio cut-offs of 0.3, 0.5, 0.8 and 1.2. Results were also similar when the analysis was restricted to either treatment-naive or treatment-experienced participants.<\/span><\/p>\n<\/div>\n

\n

The NNRTI effect compared to PIs was driven by a decrease in CD8 count (p=0.025) as CD4 changes were similar for NNRTIs and PIs (p=0.702).<\/span><\/p>\n<\/div>\n

\n

Overall, the positive difference associated with INSTI-based ART was driven by increases in CD4 count.<\/span><\/p>\n

The results were published ahead-of-print in Clinical Infectious Diseases in February 2023.<\/p>\n<\/div>\n

\n

Reference<\/span><\/p>\n<\/div>\n

\n

Sangar\u00e9 MN et al. CD4\/CD8 ratio outcome according to the class of the third active drug in antiretroviral therapy (ART) regimens: results from the Quebec Human Immunodeficiency Virus (HIV) Cohort Study,\u00a0Clinical Infectious Diseases, 2023;, ciad056,\u00a0doi: 10.1093\/cid\/ciad056. (1 February 2023).
\nacademic.oup.com\/cid\/advance-article-abstract\/doi\/10.1093\/cid\/ciad056\/7019415<\/a><\/p>\n<\/div>\n<\/div>\n

\n

\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base A retrospective analysis of 3,907 participants starting or switching ART in an observational Canadian cohort study between 2006 to 2017 reported higher CD4:CD8 ratio responses compared to PI- or NNRTI-based ART. The study included used dual …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,41],"tags":[],"class_list":["post-44778","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals","category-treatment-strategies"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=44778"}],"version-history":[{"count":6,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44778\/revisions"}],"predecessor-version":[{"id":45257,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44778\/revisions\/45257"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=44778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=44778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=44778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}